Abstract Aromatase inhibitors (AIs) have been reported to exert their antiproliferative effects in postmenopausal women with hormone receptor-positive breast cancer not only by reducing estrogen production but also by unmasking the inhibitory effects of androgens such as testosterone (TS) and dihydrotestosterone (DHT). However, the role of androgens in AI-resistance mechanisms is not sufficiently understood. 5a-Androstane-3b,17b-diol (3b-diol) generated from DHT by 3b-hydroxysteroid dehydrogenase type 1 (HSD3B1) shows androgenic and substantial estrogenic activities, representing a potential mechanism of AI resistance. Estrogen response element (ERE)-green fluorescent protein (GFP)-transfected MCF-7 breast cancer cells (E10 cells) were cultured for 3 months under steroid-depleted, TS-supplemented conditions. Among the surviving cells, two stable variants showing androgen metabolite-dependent ER activity were selected by monitoring GFP expression. We investigated the process of adaptation to androgenabundant conditions and the role of androgens in AI-resistance mechanisms in these variant cell lines. The variant cell lines showed increased growth and induction of estrogenresponsive genes rather than androgen-responsive genes after stimulation with androgens or 3b-diol. Further analysis suggested that increased expression of HSD3B1 and reduced expression of androgen receptor (AR) promoted adaptation to androgen-abundant conditions, as indicated by the increased conversion of DHT into 3b-diol by HSD3B1 and AR signal reduction. Furthermore, in parental E10 cells, ectopic expression of HSD3B1 or inhibition of AR resulted in adaptation to androgen-abundant conditions. Coculture with stromal cells to mimic local estrogen production from androgens reduced cell sensitivity to AIs compared with parental E10 cells. These results suggest that increased expression of HSD3B1 and reduced expression of AR might reduce the sensitivity to AIs as demonstrated by enhanced androgen metabolite-induced ER activation and growth mechanisms. Androgen metabolite-dependent growth of breast cancer cells may therefore play a role in AIresistance.
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Introduction
The initial use of aromatase inhibitors (AIs) provides substantial clinical benefit in postmenopausal women with hormone receptor-positive breast cancer, compared with tamoxifen. Nevertheless, some patients still relapse [3, 17] . Postmenopause, estrogens are mainly derived by aromatase from androgens (testosterone (TS) and androstenedione) biosynthesized in the adrenal glands [28] . The generated estrogens can stimulate estrogen-dependent breast cancer growth in the absence of ovarian estrogens. Androgens, such as dihydrotestosterone (DHT) and its precursor TS, exert inhibitory effects in hormone-dependent breast cancer cells [1, 11, 20] . A previous study reported that the intratumoral estradiol (E2) concentration was 0.35-fold lower in breast carcinoma tissues from patients treated with exemestane, compared with those without therapy. In contrast, intratumoral DHT and TS concentrations were 2.3-and 1.6-fold higher, respectively, in breast carcinomas treated with exemestane, compared with those without exemestane therapy [31] . It has therefore been suggested that AIs may inhibit the growth of such tumors not only by blocking the conversion of adrenal androgens to estrogens [5, 28] , but also by unmasking the inhibitory effect of androgens acting via the androgen receptor (AR) [14] . Previous reports have proposed several hypotheses to explain the mechanism responsible for AI resistance, including growth-signaling pathways independent of estrogen and estrogen receptor a (ERa) [23] , and constitutive ERa activation caused by growth factor receptor pathways [15, 25, 36] . However, few studies have investigated the process of adaptation to androgen-abundant conditions or the role of androgens in AIresistance mechanisms.
DHT is the most potent antiproliferative androgen for MCF-7 cells [14] , and binds ARs with high affinity [4] . DHT can be metabolized to 5a-androstane-3b,17b-diol (3b-diol) by 3b-hydroxysteroid dehydrogenase type 1 (HSD3B1) and aldo-keto reductase 1C3 (AKR1C3) [8, 13, 30] . 3b-Diol has been shown to bind not only ARs, but also ERa [10, 33] , and to induce growth and activation of ERa under severely estrogen-deprived conditions, representing a potential mechanism of resistance to AIs [29] . However, the effects of AI treatment on androgen metabolism are not sufficiently understood. Furthermore, 3b-diol also has substantial binding affinity for AR [33] , and the functions of androgen and 3b-diol in AI resistance remain unclear. We therefore investigated this issue using previously established estrogen response element (ERE)-green fluorescent protein (GFP)-transfected MCF-7 (E10 cells) [16, 34] . We successfully cloned two stable variant cell lines (V1 and V2 cells) that showed androgen metabolite-ER activity, by monitoring GFP expression. Using these variant cell lines, we investigated the processes of adaptation to estrogen-depleted and androgen-abundant conditions, and the role of androgens in AI-resistance mechanisms. We suggest that increased expression of HSD3B1 and reduced expression of AR might decrease the sensitivity to AIs, as indicated by enhancement of androgen metabolite-induced ER activation and cell growth. Cells and culture E10 cells were established from the human breast cancer cell line MCF-7, as described previously [16, 34] . We analyzed ER transcriptional activity in individual living cells using GFP as a reporter gene (Online Resource 1, Fig.  S1a ). Stromal cells were isolated from breast cancer tissue as described previously [34] . E10 and stromal cells were cultured in RPMI1640 medium (Sigma-Aldrich) supplemented with 10 % fetal calf serum (FCS; Tissue Culture Biologicals Inc., Tulare, CA, USA) as the regular growth medium at 37°C in a humidified atmosphere of 5 % CO 2 in air. Phenol red-free RPMI1640 (PRF-RPMI) (Gibco Brl, Grand Island, NY, USA) supplemented with 10 % dextrancoated charcoal-treated FCS was used as steroid-depleted medium for each experiment.
Materials and methods

Reagents
Screening of variant cell lines
A schema of the screening method for the variant cell lines is shown in Fig. S1B (Online Resource 1). E10 cells were cultured for 3 months in steroid-depleted medium with 100 nM TS. Five colonies showing luminescence by GFP expression were selected and seeded separately. Further screening was carried out by assessing ER activities under the following treatments. The ER activity of each clone was measured based on the proportion of GFP-positive cells in culture (ERE-GFP assay). ER activity in steroiddepleted TS-supplemented cultures was initially measured (a), and the measurement was repeated after 3 days of culture in steroid-depleted medium (b), to exclude GFPpositive clones with constitutively-activated ER. TS 100 nM and 3b-diol 100 nM were added continuously to the culture medium and ER activity was confirmed at 24 h (c), to select the clones with a high affinity for the androgen metabolite. Finally, clones that retained ER activity even after the addition of 100 nM letrozole (d), were established, and named V1 and V2 cell lines. Simultaneously, ER activities in these cell lines were confirmed to be inhibited by 1 lM fulvestrant (e). These variant cell lines were maintained in steroid-depleted medium supplemented with 100 nM TS.
Cell growth assay
For assays under defined steroid hormone conditions, cells were washed and grown in steroid-depleted medium for 3 days, then plated in 24-well culture plates at a density of 10,000 cells/well in steroid-depleted medium. The cells were incubated for 4 days in the absence or presence of the tested drugs and hormones. The cells in each well were washed and harvested, and then counted using a Sysmex CDA-500 automated cell counter (Sysmex Corporation, Kobe, Japan).
ERE-luciferase reporter assays
ERE activity in each cell line was measured using the Dual-luciferase reporter assay system (Promega, Madison, WI, USA). The estrogen reporter plasmid used, ERE-tkLuci, has been described previously [19] . The vector pRL-TK (Promega) was used as an internal control of transfection efficiency in reporter assays. Transient transfection was performed as described previously [19] . After culturing the cells for a further 24 h in the absence or presence of the tested drugs and hormones, luciferase activity was measured using the Dual-luciferase reporter assay system, according to the manufacturer's instructions.
Real-time polymerase chain reaction in cell lines
Total RNA was extracted from each cell line cultured in the indicated growth medium using Isogen (Nippon Gene Co., Ltd., Toyama, Japan), according to the manufacturer's instructions. The extracted RNA (1 lg) was converted to first-stranded cDNA primed with a random 9-mers in a 10-lL reaction volume using a Takara RNA PCR kit (AMV) Ver. 3.0 (Takara Bio Inc. Otsu, Japan). A 2-lL aliquot was used as a template for real-time polymerase chain reaction (PCR).
Real-time PCR to detect expression of the indicated mRNA was carried out according to the manufacturer's standard protocol using an Applied Biosystems StepOne real-time PCR system (Life Technologies Japan, Tokyo, Japan). The expression of the target gene relative to RPL13A internal control was calculated. All PCRs were performed in duplicate, and the specificity of the reaction was determined by melting-curve analysis at the dissociation stage. Primer data and GenBank accession numbers of reference sequences are shown in Table S1 (Online Resource 2).
Establishment of HSD3B1 over-expressing E10 cells
Construction of the HSD3B1 expression vector and control vector was carried out as follows. The SV40 early promoter, blasticidin deaminase and SV40 poly(A) gene cassette were spliced out from the pMAM2-BSD vector (Kaken Chemicals Co., Tokyo, Japan) and inserted into the BamHI site of the pRL-CMV vector (Promega). The Renilla luciferase (Rluc) gene in the generated vector was then replaced with full-length HSD3B1 cDNA (HSD3B1 expression vector) or cut-off (control vector). The HSD3B1 expression or control vector was then transfected into E10 cells using TransIT LT-1 reagent (Mirus Co., Madison, WI, USA), following the manufacturer's protocol. Cells transfected with the HSD3B1 expression or control vector were selected using 10 mg/mL blasticidin. The expression levels of HSD3B1 were analyzed by real-time PCR (Online Resource 3, Fig. S2 ).
Cell growth and ERE-GFP reporter assays in coculture system
We were unable to assess the inhibitory effect of AIs in the E10 or variant cell lines because of their low aromatase expression. We therefore used cocultures, in which cancer and stromal cells were grown separately by a membrane, but interacted via soluble factors and shared the same microenvironment, including local estrogen synthesis from androgens by aromatase in stromal cells (Online Resource 4, Fig. S3 ).
All the cell lines were washed and grown in steroiddepleted medium for 3 days. Cancer cell lines were plated in the bottom well of 24-well culture plates at a density of 10,000 cells/well in steroid-depleted medium. Stromal cells were plated in the insert layer (0.4 lm pore cell-culture insert; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) at a density of 30,000 cells/well in steroiddepleted medium supplemented with 1 lM dexamethasone to enhance aromatase gene expression [6, 34] . The cells were then incubated for 4 days in the absence or presence of the tested drugs and hormones before being subjected to cell-growth and ERE-GFP reporter assays. Cancer cells in each bottom well were washed and harvested for cell counting and ERE-GFP assay.
Statistical analyses
Analyses of cell growth, and ERE-luciferase and ERE-GFP reporter assays were performed in triplicate. Data are presented as mean ± standard deviation (mean ± SD) except for the GFP assay for the establishment of variant cell lines. The Kruskal-Wallis test was used to compare three or more independent groups. Dose-response curves for growth of each cell line induced by various steroids were compared using two way ANOVA test. The level of significance was set at P \ 0.05.
Results
Selection of two variant cell lines showing androgen metabolite-dependent ER activity
After 3 months of culture in TS-supplemented steroiddepleted medium, five clones that retained ER activity were selected. The ER activities of these clones at each step are summarized in Fig. S1B and Fig. 1 . Clones V4 and V5 retained ER activity in steroid-depleted conditions and were therefore considered to have constitutively-activated ER, by the growth factor receptor pathway or some other mechanism. ER activity in the V3 cell line was induced by TS and 3b-diol and completely suppressed by letrozole, suggesting that this ER activity depended on estrogens supplied by aromatase from TS, rather than 3b-diol. TS-induced ER activities in the V1 and V2 cell lines were inhibited by steroid depletion, and ER activities induced by TS and 3b-diol were higher than that induced by TS alone, and were not sufficiently inhibited by letrozole. These results suggested that ER activity of V1 and V2 cell lines mainly depends on androgen metabolites which are generated by aromataseindependent pathway and that V1 and V2 cell lines show high dependence on the androgen metabolite. V1 and V2 were therefore defined as variant cell lines.
Androgens and 3b-diol showed estrogenic rather than androgenic function in variant cell lines Dose-response curves for growth induced by TS, DHT, 3b-diol, and E2 are shown in Fig. 2a . Growth was stimulated in a dose-dependent manner by E2 in all cell lines, while all cell lines showed growth inhibition by TS and low-dose of DHT (1 and 10 nM). Growth inhibition by 100 nM TS and 10 nM DHT in variant cell lines was significantly weaker than in the parental E10 cell line. In contrast to the parental E10 cell line, growth in the variant cell lines was stimulated by 100 nM DHT. All cell lines were stimulated by 3b-diol in a dose-dependent manner, but low-dose 3b-diol (1 or 10 nM) stimulated growth in the variant cell lines significantly more than in the parental E10 cell line.
The results of the ERE-luciferase reporter assay are shown in Fig. 2b . DHT 100 nM induced ER activity in variant, but not parental E10 cell lines. In addition, 100 nM 3b-diol-induced ER activities were two-fold higher in variant cell lines compared with the parental E10 cell lines. ER activity induced by DHT or 3b-diol was inhibited by 1 lM fulvestrant, but not by 100 nM letrozole.
The induction of estrogen-and androgen-responsive genes by TS, DHT, and 3b-diol was analyzed using realtime PCR (Online Resource 5, Fig. S4 ). Variant cell lines showed increased induction of the estrogen-responsive genes for progesterone receptor, the transcription factor EGR3 [7] and Bcl2 by TS, DHT, and 3b-diol, compared with the parental E10 cell line. In contrast, the androgenresponsive gene KLK3 [12] was induced by TS, DHT, and 3b-diol in parental E10 cells, but not in variant cell lines.
These results indicate that the variant cell lines were adapted to androgen-abundant conditions and were hypersensitive to 3b-diol. It seems likely that this was the result of increased estrogenic, rather than androgenic functions of androgen and 3b-diol. These phenomena were also independent of aromatase activity.
Increased DHT metabolism and AR signal reduction might provide adaptability to androgen-abundant conditions mRNA levels of androgen-producing and -metabolizing enzymes and hormone receptors in the variant and parental cells lines are shown in Fig. 3 . Both variant lines (V1, V2) showed increased mRNA expression of HSD3B1 and reduced 5a-reductase type 1 and AR expression. AKR1C3 and ER were up-regulated in V2 cells. Aromatase (CYP19) and 17b-hydroxysteroid dehydrogenase type 2 were not detectable in any of the cell lines (data not shown). These results suggest that androgens may be metabolized more efficiently to 3b-diol (Online Resource 6, Fig. S5 ), which may exert estrogenic, rather than androgenic actions in variant cell lines, because of reduced androgen signal transduction.
In line with these hypotheses, HSD3B1-overexpressing E10 cells showed increased ER activity and growth stimulation by high-dose DHT (100 nM), in contrast to control E10 cells (Fig. 4a) . Furthermore, the AR inhibitor bicalutamide reduced the inhibitory effect of DHT in E10 cells, and up-regulated their sensitivity to 3b-diol (Fig. 4b) .
These results suggest that increased expression of HSD3B1 and decreased expression of AR may contribute to cell adaptation to androgen-abundant conditions, as demonstrated by the increased conversion of DHT to 3b-diol by HSD3B1 and AR signal reduction.
Variant cell lines were less sensitive to letrozole
We examined AI resistance in the variant cell lines using a coculture system to mimic local estrogen production from androgen in cancer tissues (Online Resource 4, Fig. S3 ). ER activities and cell growth were assessed under various conditions using this coculture system (Fig. 5 ). In coculture with stromal cells, 100 nM TS supplementation resulted in ER activation and growth stimulation in all cell lines, compared with untreated controls. ER activity in E10 cells induced by 100 nM TS was inhibited to untreated-control levels by 100 nM letrozole, while ER activity in variant cell lines was not completely inhibited. Cell growth of E10 a Steroid-induced growth of E10 and variant cell lines. Cells were plated in 24-well culture plates at a density of 10,000 cells/well with steroid-depleted medium, after 3 days of incubation in steroiddepleted medium. The indicated concentrations of E2, TS, DHT, 3b-diol or vehicle control (EtOH) were added to each well for 4 days. Cells from each well were then harvested and counted. Value relative to the vehicle control is shown. All data are shown as mean ± SD of three independent experiments (*P \ 0.05). b ER activity of variant cell lines induced by androgen or 3b-diol. After 3 days of incubation in steroid-depleted medium, each cell line was plated on culture plates in the same medium and incubated for 48 h. Each cell line was then cotransfected with the ERE-luciferase reporter and the pRL-luciferase plasmid as a control. Luciferase activities were assayed after culturing for a further 24 h in the presence of 100 nM TS, DHT, 3b-diol, 10 nM E2, with or without 100 nM letrozole or 1 lM fulvestrant. All data shown are mean ± SD of three independent experiments (*P \ 0.05) cell lines induced by 100 nM TS supplementation was inhibited to less than that of untreated controls by 100 nM letrozole, while cell growth of the variant cell lines was unaffected by 100 nM TS-or 100 nM letrozole-supplementation. The variant cell lines were therefore considered to be less sensitive to letrozole than the parental lines.
Discussion
In the present study, we successfully cloned two stable variant cell lines with androgen metabolite-dependent ER activity. Investigation of the process of adaptation to androgen-abundant conditions in these cell lines suggested that increased expression of HSD3B1 and reduced expression of AR might reduce the sensitivity of cells to AIs, as demonstrated by enhancement of androgen metabolite-induced ER activation and cell growth. This is the first study that has established stable variant cell lines as AI-resistant models which have androgen metaboliteinduced ER activation and cell growth mechanism.
Although this model system had some limitations in replicating the endocrinology of postmenopausal women, the androgen-abundant and estrogen-depleted culture conditions reflected AI treatment conditions, rather than simple estrogen-depleted conditions. Even without AIs, these conditions were similar to AI treatment conditions in MCF-7 cells because of their low aromatase expression [26, 27] .
We also confirmed that aromatase mRNA expression (CYP19) was not detectable in our E10 cells (data not shown).
As noted above, we aimed to establish clones based on a single mechanism, namely ER activation by androgen metabolites. We therefore used the E10 cell line to assess the ER activity of living cells and to select suitable clones. We subsequently obtained ER-dependent clones by assessing the ER activity of individual cells, and performed further screening to select clones that showed ER activity in an aromatase-independent and TS-dependent manner, excluding clones with constitutive ER activity, or clones in which ER activity was dependent on estrogens supplied by aromatase from TS. However, the following two points should be noted. The V2 cell line showed relatively high ER activity in TS-depleted conditions, suggesting the possibility of ligand-independent ER activity. ER activities of V1 and V2 were marginally inhibited by letrozole suggesting that ER activity of these cell lines may partly depends on aromatase.
Analysis of cell growth and ER activity induced by androgen or 3b-diol showed that variant cell lines were adapted for androgen-abundant conditions. Quantitative analysis of mRNA expression suggested that androgen or 3b-diol exerted estrogenic behavior independently of aromatase, as demonstrated by the increased conversion of DHT into 3b-diol and the reduced androgen signal in variant cell lines. These hypotheses support the idea that Fig. 3 mRNA expression of androgen-metabolizing enzymes and steroid receptors in E10 and variant cell lines. Total RNA was extracted from each cell line cultured in regular growth medium (Normal) or steroid-depleted medium supplemented with 100 nM TS for at least 3 days. All PCRs were performed in duplicate, and the expression of the target gene relative to RPL13A as an internal control is shown (mean ± SD) overexpression of HSD3B1 and inhibition of AR in E10 cells resulted in adaptation to estrogen-deprived and androgen-abundant conditions. A previous report showed that AR and ERa can interact directly and inhibit each other's transcriptional activity [21, 22] . Reduced AR expression may thus be one of the factors responsible for interrupting androgen signal transduction in variant cell lines.
Aromatase is highly expressed in the adipose stromal cells adjacent to the tumor in breast tumors [18, 24] . We previously reported that ERs were activated by coculture with adipose stromal cells isolated from breast tumor tissues in the presence of TS, as a substrate for aromatase [34] . The addition of TS alone had no effect on ER activity and an inhibitory effect on E10 cell growth, but TS induced ER activity and growth of E10 cells in a dose-dependent manner when cocultured with stromal cells, which effects were inhibited by 100 nM letrozole (data not shown). We used this coculture system to assess the inhibitory effect of AIs. AIs inhibit breast cancer cells by at least two separate mechanisms (Fig. 6a) . They eliminate the growth-stimulating effect of estrogens by blocking estrogen production. ER activity induced by 100 nM TS in variant cell lines was not completely inhibited in this coculture system, suggesting that they might be the result of ER activation by androgen metabolites, including 3b-diol, produced in an aromatasea b Fig. 4 Effects of HSD3B1 over-expression and androgen receptor inhibitor in E10 cells. a Steroid-induced growth of E10 cells transfected with HSD3B1 expression vector. Cells that were transfected with HSD3B1 expression vector (E10-HSD3B1) or control vector (E10-Control) were generated as described in Materials and methods. After 3 days of incubation in steroid-depleted medium, each cell line was plated on culture plates in the same medium and incubated for 48 h. Each cell line was then cotransfected with the ERE-luciferase reporter and the pRL-luciferase plasmid as a control. Luciferase activities were assayed after culturing for a further 24 h in the presence of 100 nM DHT or vehicle control (EtOH). The value relative to the vehicle control is shown. All data are shown as mean ± SD of three independent experiments (left graph). After 3 days of culture in steroid-depleted medium, these cells were plated in 24-well culture plates at a density of 10,000 cells/well with steroiddepleted medium. The indicated concentrations of DHT or the vehicle control (EtOH) were added to each well for 4 days. Cells from each well were then harvested and counted. Values relative to the vehicle control are shown (right graph). All data shown are mean ± SD of three independent experiments. b Effect of androgen receptor inhibitor bicalutamide in parental E10 cell line. After 3 days of culture in steroid-depleted medium, E10 cells were plated in 24-well culture plates at a density of 10,000 cells/well in steroid-depleted medium. The indicated concentrations of DHT, 3b-diol or vehicle control (EtOH), with or without bicalutamide (10 lM), were added to each well for 4 days. Cells from each well were then harvested and counted. Values relative to the vehicle control are shown. All data shown are mean ± SD of three independent experiments independent manner. The growth-inhibitory effect of androgens represents another possible mechanism. Androgens have been reported to have inhibitory effects in hormone-dependent breast cancer cells [1, 11, 20] . Luciana et al. [14] found that cell growth was suppressed by low androgen levels in cells not supplemented by androgens and in conditions under which androgen cannot be converted to estrogen. Letrozole therefore exerted an extra effect beyond that produced by androgen supplementation in parental E10 cells. In contrast, established variant cell lines showed letrozole-resistant ER activity and maintained their growth under TS-and letrozole-supplemented conditions in coculture with stromal cells. These results suggest that these cell lines were less sensitive to letrozole, because they showed both AR signal reduction and ER activation by androgen metabolites produced in an aromatase-independent manner. Fig. 6b shows the hypothesis of AI-resistance mechanisms that we propose from the above results.
It has been suggested that androgen metabolite-dependent ER activation and cell growth may play some roles in b This figure shows the hypothesis of AI-resistance mechanisms that we propose from the above results. AR signal reduction and ER activation by androgen metabolites produced in an aromataseindependent manner may function as an AI-resistance mechanism the mechanism of AI resistance. It is therefore necessary to investigate treatment strategies that will be effective against androgen metabolite-dependent ER activation and cell growth. 3b-Diol-induced growth in variant cell lines was inhibited by OHT, toremifene or fulvestrant, but not by AIs, suggesting a promising effect of SERMs on androgen metabolite-dependent growth mechanism (Online resource 7; Fig. S6 ). Sequential use of tamoxifen, toremifene or fulvestrant after first-line AIs has previously been suggested to be effective in patients with aromatase inhibitorrefractory advanced or metastatic breast cancer [2, 9, 32, 35] . These findings might partly account for the efficacy of sequential use of SERMs or fulvestrant after first-line AIs. Our in vitro data suggest that androgen metaboliteinduced ER activation and androgen signal reduction may play important roles in the mechanism behind AI resistance. Further investigation can contribute to the development of new therapeutic strategies and to the search for new therapeutic targets and agents against the AI resistant breast cancer. Therefore, we have initiated a clinical study to determine if androgen metabolite-dependent growth mechanisms are involved in AI-resistance in clinical breast cancer cases. Immunohistochemistry and real-time PCR analyses of nine pairs of primary and recurrent tissue samples from AI-resistant breast cancer revealed decreased AR protein expression in all cases, and increased HSD3B1 mRNA expression in five cases (data not shown). The significances of AR and HSD3B1 in clinical breast cancer are currently under further investigation.
In conclusion, we established new human breast cancer cell lines showing growth induction via ER activation by androgen metabolites. Characterization of these cell lines suggests that the androgen metabolite-dependent growth of hormone receptor-positive breast cancer may play a role in the mechanism of AI resistance. These cell lines are useful for further studying the mechanisms behind AI resistance in vitro, and could be valuable for developing diagnostic markers or novel therapeutic strategies for AI-resistant breast cancer.
